Oasmia appoints new CEO

The Board of Oasmia Pharmaceutical has today appointed Francois Martelet as the new CEO. Dr Martelet has extensive international experience of leading pharmaceutical companies. He replaces Sven Rohmann, who has been acting CEO during a crucial transition period. Mr Rohmann remains in his position as Board member and will continue to play an active role in the company’s commercialization strategy going forward.

Francois Martelet is an experienced Pharma executive with a proven track record of shaping companies and turning around underperforming units. He has held three CEO positions in the last 12 years. He has spent most of his career in the oncology field, as CEO of Avax and Topotarget, as well as in executive roles at senior level at Roche, Eli Lilly, Novartis and MSD. He has been based in six countries in Europe (including Sweden) and in the US. Francois Martelet is a French Medical Doctor, with a Masters Degree in Business. He speaks four languages, among them Swedish. Dr Martelet will take up his position on March 15, 2020.

– We have been searching for an executive with vast international experience of commercializing pharmaceutical companies, with a proven track record in oncology, with a solid network within the medical community and also who has demonstrated to be a good leader. Francois Martelet fits excellently to our needs and we look forward to having him onboard. Sven Rohmann will continue in his Board position and will actively play an important role going forward. We are very grateful and happy with the head start that Sven has given Oasmia in laying out our new strategy, commercializing Apealea and connecting with the medical world, says Jörgen Olsson, Chairman of the Board.

– I am very happy about this recruitment. I am convinced that Francois Martelet will be able to execute and further develop our strategy in an excellent way. He has a fantastic background, skills and personality to do that. He is fully committed to this task and will be able to put all energy and effort into making Oasmia a fully integrated pharmaceutical company, comments Sven Rohmann, acting CEO of Oasmia.

– Oasmia is a very interesting company in an exciting phase. The Board has sorted out some of the question marks of the past and has laid out a solid strategy to commercialize and also successfully concluded the rights issue in December. Now it is time to execute on the business plan, transforming the company, which is exactly the kind of work that really thrills me. I am excited to start and move back to Sweden where I lived many years ago, says Francois Martelet in a comment.

Telephone conference
A telephone conference with Francois Martelet, Sven Rohmann and Jörgen Olsson will be held today at 10.00 CET.
Dial-in numbers:
SE: +46856642705
UK: +443333009260
US: +18332498407

This information is information that Oasmia Pharmaceutical is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 07:30 CET on February 14, 2020.

For more information:
Urban Ekelund
IR Manager Oasmia
Phone: +46 18-50 54 40
E-mail: IR@oasmia.com

About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops, manufactures and markets new generations of drugs in the field of human and veterinary oncology. The company’s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company’s product development is based on its proprietary in-house research and company patents. Oasmia is listed on Nasdaq Stockholm (OASM) and Frankfurt Stock Exchange (OMAX.GR).